Postgenomic strategies in antibacterial drug discovery

Activity of the Investigational Fluoroquinolone Finafloxacin against Ciprofloxacin-Sensitive and -Resistant Acinetobacter baumannii Isolates

(2010) P. G. Higgins et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Resistance to Linezolid Is Mediated by thecfrGene in the First Report of an Outbreak of Linezolid‐ResistantStaphylococcus aureus

(2010) Gracia Morales et al.   CLINICAL INFECTIOUS DISEASES

Three Decades of  -Lactamase Inhibitors

(2010) S. M. Drawz et al.   CLINICAL MICROBIOLOGY REVIEWS

Anti-Infective Strategies of the Future: Is there Room for Species-Specific Antibacterial Agents?

(2010) Rudolf Then et al.   CURRENT PHARMACEUTICAL DESIGN

Structures of ClpP in complex with acyldepsipeptide antibiotics reveal its activation mechanism

(2010) Byung-Gil Lee et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Treatment with Monoclonal Antibodies againstClostridium difficileToxins

(2010) Israel Lowy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recent Advances in the Chemistry and Biology of Naturally Occurring Antibiotics

(2009) K. C. Nicolaou et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

In Vivo Pharmacodynamic Characterization of a Novel Plectasin Antibiotic, NZ2114, in a Murine Infection Model

(2009) D. Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Safety Profile of the Human Anti-Pseudomonas aeruginosa Serotype O11 Immunoglobulin M Monoclonal Antibody KBPA-101 in Healthy Volunteers

(2009) H. Lazar et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Lipopeptide Antibiotic Friulimicin B Inhibits Cell Wall Biosynthesis through Complex Formation with Bactoprenol Phosphate

(2009) T. Schneider et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Plectasin Shows Intracellular Activity against Staphylococcus aureus in Human THP-1 Monocytes and in a Mouse Peritonitis Model

(2009) K. S. Brinch et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity

(2009) J. A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Triclosan Resistance of Pseudomonas aeruginosa PAO1 Is Due to FabV, a Triclosan-Resistant Enoyl-Acyl Carrier Protein Reductase

(2009) L. Zhu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phase 1/2 Double-Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (BSYX-A110), an Antistaphylococcal Monoclonal Antibody for the Prevention of Staphylococcal Bloodstream Infections, in Very-Low-Birth-Weight Neonates

(2009) L. E. Weisman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of NXL104 in Combination with  -Lactams against Klebsiella pneumoniae Isolates Producing KPC Carbapenemases

(2009) A. Endimiani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Functional and biochemical analysis of a key series of ramoplanin analogues

(2009) Xiao Fang et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Structure-Based Virtual Ligand Screening: Recent Success Stories

(2009) Bruno Villoutreix et al.   COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING

Recent progress in fragment-based lead discovery

(2009) Michèle N Schulz et al.   CURRENT OPINION IN PHARMACOLOGY

Prospects for the next anti-Pseudomonas drug

(2009) Malcolm GP Page et al.   CURRENT OPINION IN PHARMACOLOGY

Multidrug-Resistant Gram-Negative Infections

(2009) Helen Giamarellou et al.   DRUGS

Future antibiotics scenarios: is the tide starting to turn?

(2009) Ursula Theuretzbacher   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

An oldie but a goodie – cell wall biosynthesis as antibiotic target pathway

(2009) Tanja Schneider et al.   INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY

In vitro activity of the  -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases

(2009) T. Stachyra et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity

(2009) C. Oefner et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Infections caused by Gram-positive bacteria: a review of the global challenge

(2009) Neil Woodford et al.   JOURNAL OF INFECTION

Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens

(2009) Sophie Brinster et al.   NATURE

Bacterial cell division: assembly, maintenance and disassembly of the Z ring

(2009) David W. Adams et al.   NATURE REVIEWS MICROBIOLOGY

Mass spectrometry tools for the classification and identification of bacteria

(2009) Sascha Sauer et al.   NATURE REVIEWS MICROBIOLOGY

Inactivation of DltA Modulates Virulence Factor Expression in Streptococcus pyogenes

(2009) Kathleen H. Cox et al.   PLoS One

Potential of immunomodulatory host defense peptides as novel anti-infectives

(2009) Donna M. Easton et al.   TRENDS IN BIOTECHNOLOGY

In Vitro and In Vivo Validation of ligA and tarI as Essential Targets in Staphylococcus aureus

(2008) K. Streker et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, against Linezolid-Resistant Strains

(2008) K. J. Shaw et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ

(2008) Lloyd G. Czaplewski et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

(2008) Helen W. Boucher et al.   CLINICAL INFECTIOUS DISEASES

Novel anti-infectives: is host defence the answer?

(2008) Pamela Hamill et al.   CURRENT OPINION IN BIOTECHNOLOGY

Antivirulence as a new antibacterial approach for chemotherapy

(2008) Sonia Escaich   CURRENT OPINION IN CHEMICAL BIOLOGY

Bacteriophage lysins as effective antibacterials

(2008) Vincent A Fischetti   CURRENT OPINION IN MICROBIOLOGY

Renaissance in antibacterial discovery from actinomycetes

(2008) R BALTZ   CURRENT OPINION IN PHARMACOLOGY

New agents in development for the treatment of bacterial infections

(2008) D ABBANAT et al.   CURRENT OPINION IN PHARMACOLOGY

How many modes of action should an antibiotic have?

(2008) H BROTZOESTERHELT et al.   CURRENT OPINION IN PHARMACOLOGY

Resistance redux. Infectious diseases, antibiotic resistance and the future of mankind

(2008) Julian Davies   EMBO REPORTS

An Engineered Human Antibody Fab Fragment Specific for Pseudomonas aeruginosa PcrV Antigen Has Potent Antibacterial Activity

(2008) M. Baer et al.   INFECTION AND IMMUNITY

Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: Characteristics and outcome in a series of 28 patients

(2008) Matthew E. Falagas et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

The epidemiology of antibiotic resistance

(2008) I.M. Gould   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Current Trends in Rapid Diagnostics for Methicillin-Resistant Staphylococcus aureus and Glycopeptide-Resistant Enterococcus Species

(2008) S. Malhotra-Kumar et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Physicochemical Properties of Antibacterial Compounds: Implications for Drug Discovery

(2008) Rosemarie O’Shea et al.   JOURNAL OF MEDICINAL CHEMISTRY

Oritavancin Exhibits Dual Mode of Action to Inhibit Cell-Wall Biosynthesis in Staphylococcus aureus

(2008) Sung Joon Kim et al.   JOURNAL OF MOLECULAR BIOLOGY

The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria

(2008) Jean-Marie Pagès et al.   NATURE REVIEWS MICROBIOLOGY

An Inhibitor of FtsZ with Potent and Selective Anti-Staphylococcal Activity

(2008) D. J. Haydon et al.   SCIENCE